

Special Issue

Personalized Nutrition and Diagnostic Criteria, including Serum Biomarkers, for Osteosarcopenic Obesity as a Model for Body Composition Assessment and Improvement

Message from the Guest Editor

OSO signifies the simultaneous impairment of bone (osteopenia/osteoporosis), muscle (sarcopenia), and adipose tissue (either as overt obesity, or as ectopic fat in visceral area, or as infiltrated fat into bone and muscle). OSO has been associated with poor diet and various metabolic derangements. Although some dietary recommendations for OSO have been published and some updated diagnostic criteria exist, there are no studies investigating the specific serum biomarkers to identify the simultaneous impairment of bone, muscle, and fat or each of the tissues. Additionally, there is still no consensus for diagnosis of some of the OSO components, namely, sarcopenic obesity and obesity itself, due to the high heterogeneity of the adipose tissue. Manuscripts should address the potential nutritional impact on osteosarcopenic obesity and possible diagnostic criteria for OSO, including bone, muscle/lean tissue, and/or adipose tissue. The serum biomarkers addressing any of the three tissues are of particular interest.

Guest Editor

Prof. Dr. Jasminka Ilich-Ernst

Institute for Successful Longevity, Florida State University, Tallahassee, FL 32306, USA

Deadline for manuscript submissions

closed (31 December 2020)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/34731

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).